



1623

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 01-270)

In re Application of:)
Pacciarini et al.)
Serial No.: 09/786,998) Group Art Unit: 1623
Filing Date: June 14, 2001) Examiner: Howard V. Owens Jr.
For: Use of Methoxymorpholino)
Doxorubicin for the Treatment)
of a Liver Tumor)

RECEIVED
JUL 08 2003
TECH CENTER 1600/2900

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In regard to the above identified application:

1. We are transmitting herewith the attached:
 - a. Information Disclosure Statement including 3 cited references;
 - b. PTO Form 1449; and
 - c. Return Receipt Postcard
2. With respect to additional fees:

No additional fee is required.
3. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
3. CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 30th day of June, 2003.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff

Dated: June 30, 2003

By: Stephen H. Docter
Stephen H. Docter
Reg. No. 44,659



UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 01-270)

PATENT

RECEIVED

JUL 08 2003

TECH CENTER 1600/2900

In re Application of:)
Pacciarini et al.)
Serial No.: 09/786,998) Group Art Unit: 1623
Filing Date: June 14, 2001) Examiner: Howard V. Owens Jr.
For: Use of Methoxymorpholino)
Doxorubicin for the Treatment)
of a Liver Tumor)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to the duty of disclosure provided by 35 C.F.R. § 1.56 and §§ 1.97-98, the applicants wish to make the following references of record in the above-identified application. Copies of the references are enclosed. Copies are also listed in the PTO-1449 form enclosed herewith. It is requested that the documents be given careful consideration and that they be cited of record in the prosecution history of the present application so that they will appear on the face of the patent issuing from the present application.

Portions of the references may be material to the examination of the pending claims, however no such admission is intended. 37 C.F.R. 1.97 (h). The references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative importance of any portion of the

references. This Statement is not a representation that the cited references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. sections 102 or 103.

CERTIFICATION UNDER 37 C.F.R. § 1.97(e)

The undersigned hereby certifies that each item of information cited in the present Information Disclosure Statement was cited in Search Report from the counterpart Russian no more than three months prior to the filing of the present Information Disclosure Statement.

CITED REFERENCES

Other Documents

1. V.A. Gorbunova, Intrahepatic Arterial Infusion Chemotherapy for Primary and Metastatic Cancer of the Liver.
2. Bioorganicheskaya Khimiya (Bioorganic Chemistry), E.N. Olsufjeva, Volume 18, No. 2, 1992.
3. RU 2,065,307, Specification

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff

Date: June 30, 2003

By: Stephen H. Docter
Stephen H. Docter
Registration No. 44,659